HCW Biologics

fusion immunotherapeutics, cytokine platforms, immune-cell rebalancing

modulatingimmunotherapy

hcwbiologics.com·Miami, Florida, United States·Public·$64M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-JTPW

Summary · Eternal Search editorial

HCW Biologics fusion immunotherapeutics, cytokine platforms, immune-cell rebalancing

HCW Biologics is a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapies for autoimmune diseases, cancer and senescence-associated dysplasia. Its approach is to rebalance or rejuvenate immune cells to remove disease cells or reduce senescent cells linked to chronic inflammation. The company uses proprietary TOBI and TRBC platforms to create multi-domain cytokine-based and immune-cell-targeting fusion molecules.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite38

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

HCW Biologics — Translational · Lower middle. Derived deterministically from 15 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (3 programs at…

Source: Deterministic

At a glance

Webhcwbiologics.com

HQMiami, Florida, United States

StagePublic

Publications

16 on file

012026IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells.Science advances→022026Abstract 1629: An innovative approach to improve bispecific T-cell engagers for solid tumor therapyCancer Research→0320250054 Treg-targeted therapies restrain disease in a murine model of alopecia areataJournal of Investigative Dermatology→042025Generation of HIV- and CD19-Specific TSCM CAR-T Cells by a Novel Cytokine-Based Scaffold 2319The Journal of Immunology→052025TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8 <sup>+</sup> T-cell subsets in lymph nodes and tumorsJournal for ImmunoTherapy of Cancer→062025Natural killer cell TGF-β signaling regulates senolytic activity and vascular patterning in the postnatal lungbioRxiv (Cold Spring Harbor Laboratory)→072024A "Prime and Expand" Strategy Using the Multifunctional Fusion Proteins to Generate Memory-Like NK Cells for Cell Therapy—→082024A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapyCancer Immunology Immunotherapy→092023A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in miceFrontiers in Immunology→102023Immunotherapeutic approach to reduce senescent cells and alleviate senescence‐associated secretory phenotype in miceAging Cell→112023A Novel Interleukin-2-Based Fusion Molecule, HCW9302, Differentially Promotes Regulatory T Cell Expansion to Treat Atherosclerosis in Mice—→122023767 Pre-clinical and first-in-human studies of HCW9218, a bifunctional TGF-β antagonist/IL-15 protein complex, in advanced solid tumorsRegular and Young Investigator Award Abstracts→

132023Immunotherapeutic Approach to Reduce Senescent Cells and Alleviate Senescence-Associated Secretory Phenotype in Mice—→

142022Immunotherapeutic HCW9218 Augments Anti-tumor Activity of Chemotherapy via NK Cell Mediated Reduction of Therapy Induced Senescent Cells—→

152021A Fusion Protein Complex that Combines IL12, IL15, and IL18 Signaling to Induce Memory-like NK Cells for Cancer Immunotherapy—→162021Bifunctional TGF-β trap/IL-15 Protein Complex Elicits Potent NK Cell and CD8+ T Cell Immunity Against Solid Tumors—→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

HCW Biologics

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.